Plain-English translation of NCT07933692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether —a combination medication—can better protect and repair the blood-brain barrier (a protective layer around blood vessels in the brain) in people who have recently had a stroke. Half of participants will receive the new medication combination along with standard stroke care, while the other half will receive a standard medication along with the same stroke care. Researchers will measure whether the new treatment helps the brain heal better by using an MRI scan to check blood vessel health and by tracking how well people recover.
After a stroke, the protective barrier around blood vessels in the brain can become damaged, which may slow down recovery and increase disability. Researchers believe that this medication could help repair that barrier more effectively and lead to better outcomes for stroke patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication combination or a standard medication, both given through an IV (intravenous) infusion twice daily for about 9 days, along with your regular stroke treatment. During your time in the trial, you will have MRI scans to measure changes in your brain's blood vessel health, blood tests to check for markers of recovery, and regular neurological check-ups to track how well you are recovering. The entire trial lasts approximately 9 days of treatment, with follow-up assessments to monitor your progress.
AI-generated summary from trial data · Nov 18, 2026 · Not medical advice
China